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A B S T R A C T
Purpose: Seizures frequently impact the quality of life of patients with low grade tumors. Management is
often based on best clinical judgment. We examined factors that correlate with seizure outcome to
optimize seizure management.
Methods: Patients with supratentorial low-grade tumors evaluated at a single institution were
retrospectively reviewed. Using multiple regression analysis the patient characteristics and treatments
were correlated with seizure outcome using Engel’s classiﬁcation.
Results: Of the 73 patients with low grade tumors and median follow up of 3.8 years (range 1–20 years),
54 (74%) patients had a seizure ever and 46 (63%) had at least one seizure before tumor surgery. The only
factor signiﬁcantly associated with pre-surgical seizures was tumor histology. Of the 54 patients with
seizures ever, 25 (46.3%) had a class I outcome at last follow up. There was no difference in seizure
outcome between grade II gliomas (astrocytoma grade II, oligodendroglioma grade II, mixed oligo-
astrocytoma grade II) and other pathologies (pilocytic astrocytoma, ependymomas, DNET, gangliocytoma
and ganglioglioma). Once seizures were established seizure prognosis was similar between different
pathologies. Chemotherapy (p = 0.03) and radiation therapy (p = 0.02) had a positive effect on seizure
outcome. No other parameter including signiﬁcant tumor growth during the follow up period predicted
seizure outcome. Only three patients developed new-onset seizures after tumor surgery that were non-
perioperative. Anticonvulsant medication was tapered in 14 patients with seizures and 10 had no further
seizures. Five patients underwent additional epilepsy surgery with a class I outcome in four. Two patients
received a vagal nerve stimulator with >50% seizure reduction.
Discussion: Seizures at presentation are the most important factor associated with continued seizures
after tumor surgery. Pathology does not inﬂuence seizure outcome. Use of long term prophylactic
anticonvulsants is unwarranted. Chemotherapy and radiation therapy have a favorable impact on seizure
outcome. Additional epilepsy surgery is effective.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Seizures frequently occur in patients with brain tumors of glial
origin, especially low-grade gliomas. More than 70% of those
diagnosed with a low-grade glioma will experience a seizure at
some point in the course of the disease.1,2 Recognition of patients
who are going to develop epilepsy is important in optimization of
management. Although several studies have examined the* Corresponding author at: Dartmouth Epilepsy Program, Dartmouth-Hitchcock
Medical Center, One Medical Center Drive, Lebanon, NH 03756, United States.
Tel.: +1 603 653 6118; fax: +1 603 650 6233.
E-mail address: Barbara.C.Jobst@hitchcock.org (B.C. Jobst).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.05.014importance of seizures as a prognostic variable for survival in
patients with brain tumors3 and the impact of tumor surgery on
seizure outcome.4 Few have addressed the optimal seizure
management or identiﬁed the prognostic factors for seizure
outcome.5,6 In addition, most previous studies have been
conducted before the widespread use of chemotherapy and
radiation therapy for low grade tumors.4,7 In this study we
examined factors that predict seizure prognosis in patients with
low-grade tumors that may aid in seizure management.
2. Materials and methods
This retrospective study included patients with the diagnosis
of supratentorial low-grade tumors evaluated and treated atvier Ltd. All rights reserved.
Table 1
Demographics data of all patients (n = 73).
Characteristic Median Range
Age at tumor diagnosis* 40.2 years 8.0–79.8 years
Follow-up period 3.8 years 1.0–20.0 years
Survival time for deceased patients (n = 9) 3.9 years 1.7–12.8 years
Characteristic Number Percent
Female 34 47
Male 39 53
Pediatric patients (<18 years old) 9 12
Alive at time of data collection 64 88
* Demographics were not signiﬁcantly different of patients with gliomas Type II
and other pathologies (p > 0.05) with the exception of age, which was on average
lower in the patient with other pathologies than with gliomas grade II (mean age
grade II 43.7 years, other pathologies 32.8 years; p = 0.005).
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Patients included had the pathologic diagnosis of World Health
Organization (WHO) grade I pilocytic astrocytoma, WHO grade II
astrocytoma, WHO grade II oligodendroglioma, WHO grade II
mixed oligo-astrocytoma, ganglioglioma/gangliocytoma, epen-
dymomas, subependymoma, dysembryoplastic neuroepithelial
tumor (DNET), or neurocytoma. As the low grade tumors included
a variety of tumors with different characteristics and behavior,
WHO grade II astrocytoma, WHO grade II oligodendroglioma,
WHO grade II mixed oligo-astrocytoma were grouped and
analyzed as grade II gliomas, while the remaining pathologies
were summarized as other pathologies. All patients were
examined in the neuro-oncology clinic. Follow-up data with
records of surgery, seizure outcome, and tumor outcome were
available. All subjects underwent at least one surgical interven-
tion for pathologic diagnosis which was categorized as biopsy,
partial resection, or total resection as determined by the
neurosurgeon. Electrocorticography to guide tumor resection
was not performed. Patients with biopsy only were included,
because although without therapeutic intent, it results in
alteration of cerebral neurophysiology and seizure risk. We
intended to reﬂect a patient population that is routinely seen in a
neurooncology or epilepsy practice and provide some guidelines
for treatment. All patients had a minimum of one year of follow-
up, with a median follow up of 3.8 years and range between 1 and
20 years. All seizure data and outcomes were reviewed by an
epileptologist (BCJ).
Tumor data collected included date of diagnosis, pathological
diagnosis, brain location, type of surgery, cytogenetic status (1p
and 19q), radiotherapy, chemotherapy, chemotherapeutic agents,
tumor progression, and survival. Cytogenetic status was deter-
mined only in patients with an oligodendroglioma component and
was not available in all patients. Pathologic diagnosis was
independently performed without knowledge of seizure status
or prognosis.
Signiﬁcant tumor growth was deﬁned as an increase in tumor
size as evidenced by MRI imaging. Signiﬁcant tumor growth was
deﬁned as a 25% increase in the area measured by perpendicular
diameters of the tumor on T2 weighted sequences, which equates
to a clinically meaningful progression that in clinical practice
would warrant further intervention.
Seizure data included the number and type of seizures the
patient experienced before tumor surgery, during the periopera-
tive period (up to 2 weeks after tumor surgery), and more than 2
weeks after tumor surgery. Seizures were classiﬁed as generalized
tonic–clonic, focal with loss of consciousness, or focal without loss
of consciousness. Seizures outcome was assessed using Engel’s
classiﬁcation at last follow-up.8 For patients who developed
seizures after surgery, the time of ﬁrst seizure was used as the
starting point for the Engel classiﬁcation. Although Engel’s
classiﬁcation was established for seizure outcome after epilepsy
surgery, it is frequently also used to determine seizure outcome
after other interventions.1 Patients who did not experience any
seizures before or after surgery were classiﬁed as having no
seizures ever. Postoperative EEG was not consistently obtained to
allow meaningful data analysis. All available information for each
patient was entered into a standardized database. The study was
reviewed and approved by the Dartmouth College Committee for
the Protection of Human Subjects.
2.1. Statistical analysis
Two sets of analyses were carried out. First we investigated the
predictor variable for seizures at presentation prior to tumor
surgery. Second we investigated the predictors for seizure freedom
post surgery. Parameters including tumor location, tumor type, useof antiepileptic drugs prior to surgery, length of follow-up,
chemotherapy or radiation therapy, gender, history of generalized
tonic–clonic seizures and age were analyzed using univariable
models and multivariable regression. Additional univariate analy-
sis was performed to compare the grade II tumor pathology to
other pathologies. Kaplan–Meier analysis was employed to
analyze factors that inﬂuenced whether a patient had a least
one seizure in the year prior to their last follow-up. Statistical
analyses were carried out in SPSS (version 18, Chicago, IL).
3. Results
3.1. Patient population and tumor characteristics
The demographic characteristics of the 73 patients identiﬁed
are displayed in Table 1. Besides age there was no signiﬁcant
difference between grade II tumors and other pathologies. Tumor
type, tumor location, and type of treatment are shown in Table 2.
Fig. 1 shows the breakdown of seizure occurrence in the 73
patients. Of the 54 (74.0%) patients who had a seizure ever, 46
(85.2%) experienced at least one seizure before their ﬁrst surgery
and pathologic diagnosis, 5 (9.2%) in the perioperative period and 3
(5.6%) after more than 2 weeks after ﬁrst tumor surgery. Twenty-
seven tumors were tested for deletion of 1p or 19q and the results
are summarized in Table 2.
3.2. Tumor surgery
Initial surgical procedures are listed in Table 2. Three of the 15
patients who had an initial biopsy had a resection within three
month and are included in the resection groups. Patients with
other pathologies were more likely to have had a complete
resection at initial surgery than patients with grade II tumors
(p = 0.018). Thirty-two patients (43.8%) had signiﬁcant tumor
growth during the follow-up period; there were 23/46 (50%)
patients in the grade II glioma patients that had signiﬁcant tumor
growth and 9/27 (33%) patients with other pathologies who had
signiﬁcant tumor growth (p > 0.05). 21 had additional tumor
related surgical procedures. Of the 21 who had additional surgery,
one patient had a biopsy, 6 patients had a partial resection, and 14
had a total resection. Six patients had a third surgery because of
signiﬁcant tumor growth. One had a biopsy and ﬁve had further
resections.
3.3. Temporal proﬁle and characteristics of seizures
There were 46 patients with a ﬁrst seizure preceding any
surgical intervention for the brain tumor. Univariable analysis of
seizure occurrence revealed that only tumor location (p = 0.034)
and tumor pathology (p = 0.019) are signiﬁcantly correlated with
Table 2
Tumor pathology, location, and treatment.
Characteristic Number of patients (%) Never had seizures (%) Had seizures ever (%)
Tumor pathology
Pilocytic astrocytoma 6 (8.2) 4 (66.7) 2 (33.3)
Astrocytoma grade II 14 (19.2) 2 (14.3) 12 (85.7)
Mixed oligo-astrocytoma and oligodendroglioma grade II 32 (43.8) 7 (21.9) 25 (78.1)
Ganglioglioma/gangliocytoma and DNT 15 (20.5) 2 (13.3) 13 (86.7)
Ependymoma/subependymoma and neurocytoma 6 (8.2) 4 (66.7) 2 (33.3)
Tumor location
Frontal lobe 36 (49.3) 10 (27.8) 26 (72.2)
Temporal lobe 21 (28.8) 2 (9.5) 19 (90.5)
Parietal–occipital lobe 8 (11.0) 1 (12.5) 7 (87.5)
Intraventricular 8 (11.0) 6 (75.0) 2 (25.0)
First surgical intervention
Biopsy 12 (16.4) 2 (16.7) 10 (83.3.)
Partial resection 20 (27.3) 6 (30.0.) 14 (70.0)
Total resection 41 (56.1) 11 (26.8) 30 (73.2)
Tumor progression 32 (43.8) 6 (18.8) 26 (81.3)
Tumor treatments
Chemotherapy 27 (37.0) 2 (7.4) 25 (92.6)
Radiation therapy 25 (34.2) 3 (12.0) 22 (88.0)
Fig. 1. (A) Flowchart for the distribution of patients according to seizure outcome. (B) Relationship between increase tumor size and postsurgical seizures in all patients who
had presurgical seizures (n = 46), stratiﬁed by initial surgical procedure.
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signiﬁcant variable for predicting occurrence of pre-surgical
seizures was tumor pathology (p = 0.05). Gangliogliomas/gang-
liocytomas and DNET were most commonly associated with
seizures (32.5 more likely than pilocytic tumors; 95% CI: 2.4–443),
followed by WHO grade II astrocytomas (12.5 more likely than
pilocytic tumors; 95% CI 1.1–143), oligodendrogliomas or mixed
oligo-astrocytomas (8.3 more likely than pilocytic astrocytomas
95% CI: 0.9–80). Ependymomas, subependymomas and neurocy-
tomas had a low risk for seizures at diagnosis similar to the risk
associated to pilocytic astrocytomas. Cytogenetic status (p = 0.76)
and survival (p = 0.32) were not signiﬁcantly associated with
seizures preceding surgery. Eleven patients (23.9% of all patients
with seizures preceding tumor surgery) had more than three
seizures at least 12 months before pathological tumor diagnosis
which would fulﬁll criteria for the clinical diagnosis of chronic
epilepsy.
Twenty (43.5%) of the 46 seizure patients had a secondarily
generalized tonic–clonic seizure, 15 (32.6%) had focal seizures
without loss of consciousness, and 11 (23.9%) had focal seizures
with loss of consciousness as their initial seizure.
3.4. Seizure outcome
Table 3 displays Engel’s classiﬁcation of outcomes in all 73
patients at last follow-up and Fig. 1 displays detailed seizure
outcomes.
Thirty-ﬁve of 46 patients with pre-operative seizures (74.1%)
had seizures after their ﬁrst surgery. Twenty-four (52.3%) were
seizure free at last follow-up. Tumor pathology, cytogenetic status,
age at diagnosis, type of ﬁrst seizure and tumor location were not
signiﬁcant predictors of seizure freedom at last follow-up. Grade II
gliomas were not signiﬁcantly different from other pathologies in
terms of seizure outcome (Table 3), but were more likely than
pilocytic astrocytomas and ependymoma, to present with seizures.
Eight (29.6%) of 27 patients who had no seizures before their
initial surgery experienced seizures; 5 had their ﬁrst seizure in the
perioperative period (<2 weeks) and 3 more than 2 weeks after
tumor surgery. Two of the ﬁve patients with perioperative seizures
were on prophylactic AEDs. Postoperative seizure onset apart from
the perioperative period occurred in the ﬁrst post-surgical year for
two patients and in the third year after surgery in one patient.
Seizure onset was associated with signiﬁcant tumor growth in two
patients and was not associated with signiﬁcant tumor growth in
the remaining one.
Twenty-two patients of 46 with pre-surgical seizures had an
initial total resection. Sixteen (72.7%) continued to have seizures,
but twelve of 16 (75.0%) became eventually seizure free during
their last year of follow-up. Only 5 of 22 patients (22.7%) patients
who had total resection and post-surgical seizures also had tumor
progression. Thirteen of 46 patients with pre-surgical seizures had
a partial resection as their ﬁrst surgery. Ten of the 13 (76.9%) had atTable 3
Engel classiﬁcation of outcomes after surgery. Seizure outcome in all patients, in patient
seizures outcome whether patients had grade II gliomas or other pathologies.
Engel class All patients (n
Patients with no seizures ever 19/73 
Patients with seizures 54/73 
Class I (free of disabling seizures) 25/54 
Class II (rare disabling seizures) 7/54 
Class III (worthwhile improvement) 2/54 
Class IV (no worthwhile improvement) 20/54 
Patients who were seizure free >12 months at last follow-up 30/54 least one seizure post-operatively. Six of the 10 (60%) were seizure
free at last follow-up. Total or partial resection did not inﬂuence
seizure outcome (p > 0.05) in a regression model, that corrected
for tumor pathology as well as in a Chi-square analysis that
compared between the grade II gliomas and other pathologies.
Of the 40 patients who had seizures after initial tumor surgery
outside of the perioperative period, 23 (57.5%) were seizure-free
for at least one year during the post-surgical follow-up period.
Thirteen (56.5%) of these patients had recurrent post-surgical
seizures after at least one year of seizure freedom. Recurrence of
post-surgical seizures occurred in the same year as signiﬁcant
tumor growth was noted in 7 (53.8%) of the 13 patients.
Seven (63.6%) of the 11 patients who were considered to have
chronic epilepsy had at least one seizure after their ﬁrst surgery for
the tumor. Five (45.5%) were seizure free at last follow-up. There
was no correlation between a diagnosis of chronic epilepsy and
seizure outcome at last follow-up.
Signiﬁcant tumor growth occurred in 32 (43.8%) of 73 patients
in this study. Nineteen (59.4%) of the patients who had signiﬁcant
tumor growth were seizure free at last follow up. There was no
correlation between signiﬁcant tumor growth, pathology and
seizure outcome at last follow-up (Fig. 1B).
Chemotherapy and radiation therapy had a positive effect on
seizures in a Kaplan–Meier analysis (Fig. 2). Patients with pre-
surgical seizures who had radiation or chemotherapy were less
likely to have seizures at last follow-up than patients who did not
(radiation: p = 0.02, chemotherapy: p = 0.03). The Kaplan–Meier
analyses for all other factors (age, gender, tumor pathology, tumor
location, cytogenetic status) were not signiﬁcant in terms of
seizure outcome after surgery.
All 54 patients with seizures received AED; 44 patients were
still receiving medication at last follow-up. For 14 patients, AEDs
were discontinued on clinical grounds (no further seizures). Eight
of these patients had both pre- and post-surgical seizures, three
had pre-surgical seizures only, two had perioperative seizures
only, and one had post-surgical seizures only. Of these 14 patients,
10 (71.4%) had no further seizures, while 4 (28.6%) patients
experienced a seizure after discontinuing the medication. In three
of these four patients, the recurrence of seizures after discontinu-
ing AED was associated with tumor progression. Patients with
perioperative seizures who discontinued AED during the ﬁrst year
after surgery had no further seizures. Of the other 10 patients who
discontinued AED, all were seizure free while taking AED for 1–4
years before tapering. Due to multiple medications and dosages
used, further statistical analysis regarding which AED is more
effective was not possible.
Two patients in this study received a vagal nerve stimulator
implant, which reduced their seizure frequency by more than 50%.
Both of these patients previously underwent previous tumor
resections. Five patients whose seizures continued after tumor
resection subsequently underwent a detailed work-up for further
epilepsy surgery and had further resections. In four of the ﬁves with grade II gliomas and other pathologies. There was no signiﬁcant difference in
 = 73) Grade II gliomas
n = 46
Other pathologies
n = 27
p-Value
26.0% 9/46 19.6% 10/27 37.0% 0.10
74.0% 37/46 80.1% 17/27 63.0% NS
46.3% 16/37 43.2% 9/17 52.9% NS
13.0% 6/37 16.2% 1/17 0.6% NS
3.7% 1/37 0.3% 1/17 0.6% NS
37.0% 14/37 37.8% 6/17 35.2% NS
55.6% 19/37 51.3% 11/17 64.7% NS
Fig. 2. Kaplan–Meier analysis of seizure freedom during follow-up from time of surgery for 46 pre-surgical seizure patients who underwent radiation therapy or
chemotherapy compared to patients who did not. All patients in our study who did not undergo chemotherapy had less than 10 years of follow-up so the ‘‘no chemotherapy’’
line is shorter than the ‘‘chemotherapy’’ line on the graph. This was not a function of survival.
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patients had an Engel class I outcome after epilepsy surgery and
one patient had a class IV outcome due to tumor progression.
4. Discussion
Seizures and their management have a major impact on the
quality of life of patients with low grade tumors. In this study we
identiﬁed pathology as the only factor associated with seizures at
presentation. Once seizures were established the seizure outcome
was independent of underlying pathology with eventual seizure
freedom achieved in about 50% of patients. Pathology did not
inﬂuence ﬁnal seizure outcome. Patient with pilocytic astrocyto-
mas and ependymomas are less likely to present with seizures,
however once seizures are established, the seizure prognosis was
not any different than in grade II gliomas. Patients who had
seizures preceding tumor surgery were more likely to have post-
surgical seizures, although, interestingly, the type of resection,
increase in tumor size and the number of preoperative seizures did
not correlate with seizure outcome.
Some studies report more favorable seizure outcomes for
patients who underwent gross-total resection of a low-grade
glioma,1,9,10 but, as in our study, others have not observed
correlation between extent of resection and seizure outcome.11
The pathophysiologic mechanism for seizure generation may be
dependent on other factors such as involved neuronal networks or
blood–brain barrier dysfunction and independent on extent of
tumor removal. Seizure outcome in our study is less favorable than
in other studies,1,4,10,12 which is likely a function of our prolonged
follow up time and patient selection. Our study mirrors a
population routinely seen in a neuro-oncology clinic and does
not only focus on patients with intractable epilepsy,7,12 certain
tumor locations6 or non-progressive tumors.7,12 Previous studies
focused on seizures at presentation, included a wide variety of
tumors including glioblastoma,13–15 or limited postsurgical follow
up to twelve months.16
Our results strengthen the recommendation that prophylactic
AED treatment is not indicated for patients with low grade
gliomas.17,18 In the perioperative period new onset seizures occurin a small number of patients and in most cases they do not recur.
Furthermore, patients without seizures before tumor surgery are
unlikely to develop seizures unless associated with increase in
tumor size.1,13 Nevertheless, in clinical practice prophylactic AED
are frequently continued for prolonged periods of time.19
We identiﬁed that treatment with radiation and chemotherapy
has a positive effect in the control of seizures. Our study accounts
for currently used chemotherapy agents, like temozolomide, and
more targeted radiation therapy techniques compared to older
studies.10,7 A positive effect of radiation on seizures was suggested
in nine patients by Chalifoux and Elisevich20 and was conﬁrmed by
our study. Pace et al. reported a ‘‘relevant’’ effect of chemotherapy
on seizure control in 31 patients treated effectively with
temozolomide.21 A very recent cohort study suggested a similar
positive effect of temozolomide.22 It is possible that chemotherapy
and radiation have a modulatory effect that affects seizure
generation. Peritumoral processes may play a signiﬁcant role in
seizure generation that may be inﬂuenced by radiation or
chemotherapy.23
The small sample size prevents our study from providing a
deﬁnite recommendation when to discontinue AED treatment in
the patient with low grade tumors. Patients who had been seizure
free for prolonged periods of time were offered to discontinue AED.
Most of them did not have recurrent seizures apart from the setting
of tumor recurrence. It seems clinically appropriate to discontinue
AED in patients with pre-operative seizures who do not have
seizures for more than 2 years after tumor surgery or treatment
with radiation and chemotherapy and without evidence of
signiﬁcant increase in tumor size. Nonetheless, approximately
25% of those patients will have a recurrent seizure, most often
associated with a signiﬁcant increase in tumor size. Unfortunately
due to various AED regimens, further analysis was not possible to
assess efﬁcacy of AED or establish differences between AED. Future
controlled studies are needed to establish guidelines for dis-
continuing AED and to determine efﬁcacy in low-grade glioma
patients.
Although epilepsy surgery was only performed on ﬁve patients
in our study, it led to improved seizure outcome for four of these
patients. This indicates that epilepsy surgery should be considered
C.A. Kahlenberg et al. / Seizure 21 (2012) 540–545 545as a possible option for treating refractory seizures in low-grade
tumor patients. Neuro-oncologists and epileptologists should be
encouraged to cooperate to not only limit tumor growth but also to
treat seizures which can signiﬁcantly impair quality of life. In a
previous study, epilepsy surgery was successful in 12 of 14 patients
with temporal lobe tumors and medically refractory epilepsy,24
however inclusion criteria for tumors differ in neuro-oncology and
epilepsy-related studies.
In conclusion, the greatest risk factor for seizures in low-grade
tumors is previous seizures. Pathology does not inﬂuence seizure
outcome once seizures are established. Prophylactic AEDs are not
indicated. Chemotherapy and radiation therapy have a positive
effect on seizures, but further studies are needed to examine the
interactions of AED and chemotherapy. In addition, controlled
studies are needed to examine when it is appropriate to
discontinue AEDs and which AED is most efﬁcient.
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